Reading LBRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LBRX free→LB Pharmaceuticals, Inc. (LBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-07-06
Watch· this week
$33.41-0.06%
Close 2026-07-06 · 1-day change
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
The thesis is that LBRX's growth potential is supported by recent analyst ratings. The company has not released earnings data yet, so its financial performance is unclear. LBRX trades at a valuation that lacks a clear multiple, making it hard to assess. The market is currently in a "Mania" cycle, which can affect stock prices. A specific risk is that the next-quarter miss probability is at 55%. Peer multiples imply a price about 13% above where it trades. This read is provisional.
as of 2026-07-06
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $958.66M
- Employees
- —
- IPO date
- 2025-08-22
- Next earnings
- 2026-08-11
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 1 valuation methods, at three horizons. Current price $33.41. As of 2026-07-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Fair value· primary
$38.50
Range $38.50 – $38.50
vs price: -13% below
Method agreement : high · 1 method
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
3-year
—consensus
Range — – —
vs price: —
Method agreement —
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
5-year
—consensus
Range — – —
vs price: —
Method agreement —
A long-thesis check that carries the widest uncertainty of the three horizons.
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
high confidence
We can't anchor a clean multiple for LBRX right now, so treat our $38 fair value as low-confidence. Analysts target $36–$45. Not investment advice.
Multiple (multiple)
—
peer — · own history —
Premium
—
Growth the price needs
-17%
our forecast —
Our fair value
$38.50
range $38.50 – $38.50
Analyst range(a guide on our number, not a target)Our number is in the analyst range
(median $38.50) · 4 analysts · as of 2026-05-17
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
12-month view
What's priced in
The price sits about 17% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Compared to peers
Not enough peers to compare yet.
Compared to its own history
Self-history needs ~20 months of data.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
Not enough signal yet.
Earnings quality
Not enough signal yet.
Macro sensitivity
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, long-term interest rates, the US dollar, real (inflation-adjusted) rates, Fed net liquidity.
Management & capital allocation
neutral6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 48% for the rest of the cohort, n=4965).
66th pctl · Health Care
Not investment advice. As of 2026-07-06.
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Bullish5 analysts, 100% Buyfor period ending 2026-09-30
Why this setup
Consensus revisions
EPS estimate $-0.94 → $-0.95 (-0.6% / 30d). 4 raised, 0 cut, 5 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
Material events
0 positive, 0 negative / 30d.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: by revenue growth.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Provisional
- Earnings discipline
- weak
- Post-call reaction
- neutral
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-07-06
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Long-term · 1–3 yr
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$233.
How much price usually moves either way.
On a bad day, this stock has moved -$622.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,782.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-07-06
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
Our read has strengthened. It is supported by analyst_valuation.
as of 2026-07-06
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- Either wayHigh confidenceWeeksactive 17d
Watch for Q2 earnings results on August 11
Why it matters: Earnings results show financial health and how well the company is doing.
What confirms / what disproves
Confirms one read:Earnings results show revenue growth exceeding 10% year over year.
Confirms the other:Earnings results show revenue drop or do not meet analyst expectations.
Sector context
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-05-261mo agoInvesting.com South Africa
Analyst buy rating supports positive outlook for the stock.
ReinforcesUnconfirmed report
This sector is also watching
- Watch for Health Care revenue growth to re-accelerate above 10%
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting LBRX and other Healthcare names. Worth watching these names for early signals.
- If the Fed starts cutting rates from the current 3.63%, that would be a tailwind for LBRX and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping LBRX and other Healthcare names could fade. Watch these names for early warning.
- If GDP growth slows materially from the current 2.7% (say, below 2%), it hits LBRX and other Healthcare names harder than the average stock, since the sector is growth-sensitive.
- If inflation reaccelerates, say headline CPI back above 3.5% (currently 2.8%), that would delay Fed rate cuts, which is a drag on LBRX and other Healthcare names.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-1027d agoItem 5.02
Chief Medical Officer — Anna Eramo, M.D.: Dr. Anna Eramo resigned from her position as Chief Medical Officer for personal reasons and will transition to an advisor role.
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.